Coffee and Caffeine on a GLP-1 Microdose: Absorption, Appetite, Nausea, and Timing
Nothing in the pharmacology forbids coffee on a GLP-1 medication. Plenty in the pharmacology changes how it lands. The peak arrives later, the stomach holds the acid longer, and a drink that used to be a habit can quietly become a meal. Here is what the evidence supports and what it does not.
27%
LOWER FIRST-HOUR EXPOSURE TO AN ORAL MARKER DRUG ON SEMAGLUTIDE, WITH NO CHANGE IN TOTAL EXPOSURE, PER THE PRESCRIBING INFORMATION
60%
MORE COLONIC MOTOR ACTIVITY AFTER CAFFEINATED COFFEE THAN AFTER WATER IN THE RAO 1998 STUDY
8.8 h
BEFORE BEDTIME, THE CUTOFF FOR A STANDARD COFFEE TO AVOID MEASURABLE SLEEP LOSS IN THE GARDINER 2023 REVIEW
A man three weeks into a low-dose semaglutide protocol drinks his usual coffee at 7 am, feels nothing by 7:30, and pours a second. By 8:15 his hands are unsteady, his heart is tapping, and he is faintly nauseous, and he blames the medication. The medication is involved, but not in the way he thinks. It delayed the first cup. The second one arrived on top of it.
Coffee is the most widely consumed psychoactive substance in the world, and questions about it are among the most common that people starting a GLP-1 medication ask. The answers online range from "avoid it entirely" to "it boosts the effect," and neither is supported. The pharmacology is more interesting than either extreme, because a GLP-1 receptor agonist changes the stomach, the appetite, the gut, and the fluid balance that coffee interacts with, and each of those changes has a documented, measurable consequence.
What follows covers whether there is any interaction at all, what delayed gastric emptying does to caffeine absorption, how much coffee actually adds to appetite suppression, why it can aggravate nausea and reflux, why it can help with constipation, what it does to blood pressure, heart rate, and sleep, and how it interacts with glucose. It closes with a timing table built around the situations that come up most often.
Key takeaways
- •There is no listed drug interaction between caffeine and semaglutide, tirzepatide, or any other GLP-1 receptor agonist, and the FDA considers up to 400 mg of caffeine a day a level not generally associated with harm in healthy adults.
- •GLP-1 medications slow gastric emptying, and the Ozempic prescribing information reports a 27 percent reduction in first-hour exposure to oral paracetamol with no change in total exposure, so a caffeine peak is expected to arrive later and flatter rather than smaller overall.
- •Caffeine raises resting metabolic rate by roughly 3 to 4 percent for a few hours and has a small, inconsistent effect on energy intake, which is negligible next to the 24 to 35 percent intake reduction produced by semaglutide.
- •Reflux disease was reported in about 5 percent of adults on semaglutide 2.4 mg versus 1 percent on placebo, and coffee stimulates gastric acid, so coffee on an empty, slow-emptying stomach is a common nausea trigger that timing usually fixes.
- •Caffeinated coffee stimulated colonic motor activity about 60 percent more than water in the Rao 1998 study, which makes it a useful first response to the constipation that affected 24 percent of adults on semaglutide 2.4 mg.
- •A standard coffee should be finished about 8.8 hours before bedtime to avoid measurable sleep loss, and a blended or syrup-based coffee drink of 250 to 380 kcal can displace the protein meal a reduced appetite has room for.
Can you drink coffee while microdosing a GLP-1 medication?
Yes. No GLP-1 receptor agonist lists caffeine as an interacting substance in its prescribing information, coffee was not restricted in the STEP or SURMOUNT trial protocols, and no case series has linked the two. Caffeine is metabolised almost entirely by the liver enzyme CYP1A2, while semaglutide and tirzepatide are peptides broken down by proteolysis and do not touch the cytochrome system at all. There is no shared pathway for one to interfere with the other.
The dose ceiling for caffeine is the same as it would be without the medication. The US Food and Drug Administration cites 400 mg a day for healthy adults as a level not generally associated with dangerous or negative effects, and the European Food Safety Authority reached the same figure in its 2015 opinion, adding a single-dose limit of 200 mg. Four 8 oz cups of brewed coffee, or about two 16 oz cold brews, reach that ceiling. Pregnancy, arrhythmia, uncontrolled hypertension, and anxiety disorders each lower it, and none of those thresholds changes because a GLP-1 medication is in the picture.
What does change is the context the caffeine arrives in. A GLP-1 receptor agonist slows the stomach, reduces the appetite, blunts thirst, raises resting heart rate by a few beats, and shifts the gut toward constipation. Each of those effects is also something coffee acts on, so the sensible questions are not about interaction but about how the two overlap in the same body over the same morning.
Typical caffeine content by drink, mg
Representative mid-range values. Brewed coffee varies from about 70 to 140 mg per 8 oz depending on bean, roast, and method, and cold brew concentrates can exceed 300 mg per 16 oz.
A single large cold brew can deliver as much caffeine as two standard cups. Portion size matters more than drink type.
Does a GLP-1 medication change how caffeine is absorbed?
Almost certainly, and the direction is later and flatter rather than less. Caffeine is absorbed mainly in the small intestine, with only a minor share taken up through the stomach wall, so it has to wait for the stomach to release it. GLP-1 receptor agonists slow that release. Semaglutide, tirzepatide, and liraglutide all delay gastric emptying, most strongly in the first weeks of a dose and most strongly in the hours after an injection.
The best available measurement uses paracetamol, the standard probe for gastric emptying in drug studies. The Ozempic prescribing information reports that semaglutide reduced paracetamol exposure in the first hour after a dose by about 27 percent and its peak concentration by about 23 percent, while total exposure over five hours was unchanged. Friedrichsen and colleagues reported the same pattern with semaglutide 2.4 mg in 2021. Paracetamol and caffeine are both small, lipophilic molecules absorbed in the upper small intestine, so the caffeine curve is expected to shift the same way, although nobody has measured it directly.
The practical consequence is the one in the opening paragraph. Caffeine normally peaks in the blood at 30 to 60 minutes. On a GLP-1 medication that peak may not arrive until 60 to 90 minutes, and it is lower when it does. A person who judges the first cup a failure at 30 minutes and pours a second is not compensating for a weaker dose. Both doses are still coming, and they will arrive together. The half-life of caffeine, around five hours in most adults, is unaffected, so the later start also means a later finish.
Illustrative plasma caffeine curve after one cup, normal versus delayed gastric emptying
Conceptual curves indexed to the normal peak as 100. The shape is drawn to match the paracetamol absorption data reported for semaglutide, in which first-hour exposure fell about 27 percent while total exposure was unchanged. Caffeine has not been measured directly on a GLP-1 medication.
- Normal gastric emptying
- Delayed emptying on a GLP-1
At 30 minutes the delayed curve is less than half the normal one. By two hours the two are nearly the same. The caffeine did not go missing.
Does coffee add to the appetite suppression of a GLP-1 microdose?
Barely. Coffee has a small, inconsistent effect on appetite and a small, consistent effect on energy expenditure, and both are tiny against what a GLP-1 medication does. Schubert and colleagues reviewed the appetite literature in the International Journal of Food Sciences and Nutrition in 2017 and concluded that coffee consumed 30 minutes to four hours before a meal reduced intake at that meal in some studies and not in others, with no reliable dose relationship and no evidence of an effect on total daily intake.
The metabolic side is better established but not larger. Dulloo and colleagues showed in the American Journal of Clinical Nutrition in 1989 that 100 mg of caffeine raised resting metabolic rate by 3 to 4 percent for about 150 minutes in both lean and formerly obese adults. Spread over a day of moderate intake that is on the order of 50 to 100 kcal. Semaglutide 2.4 mg, for comparison, reduced ad libitum energy intake by about 35 percent in the Friedrichsen 2021 study, and semaglutide 1.0 mg by about 24 percent in the Blundell 2017 study. A microdose sits somewhere below those figures, and coffee sits far below the microdose.
The larger risk runs the other way. Appetite suppression makes it easy to skip a meal, and a coffee shop drink is the most socially normal way to do that. A 16 oz latte with whole milk is around 190 kcal and 10 g of protein, which is a reasonable snack. A flavoured version with syrup is around 250 kcal, and a blended coffee drink with whipped cream is around 380 kcal with about 5 g of protein, most of it sugar and fat. On a protocol where the daily protein target of 1.2 to 1.6 g/kg is already hard to reach, a drink that fills the stomach and delivers almost none of it is working against the goal.
Approximate energy and protein content of common coffee drinks
Representative values for chain coffee shop sizes. Exact figures vary by milk, syrup, and portion.
The amber bars are drinks that function as a small meal without delivering what a small meal should. The protein content of the blended drink is about 5 g.
Does coffee make GLP-1 nausea and reflux worse?
Often, and the mechanism is straightforward. Coffee stimulates gastric acid secretion, both through caffeine and through other compounds that persist in decaf, and it relaxes the lower oesophageal sphincter in some people. A GLP-1 medication then holds the stomach's contents, acid included, for longer than usual. The Wegovy prescribing information lists gastro-oesophageal reflux disease in about 5 percent of adults on semaglutide 2.4 mg versus about 1 percent on placebo, dyspepsia in 9 percent versus 3 percent, and nausea in 44 percent versus 16 percent. Coffee does not cause those numbers, but it lands on top of them.
Timing is the variable that matters most. Nausea on a GLP-1 medication clusters in the first one to two days after an injection and in the first weeks after a dose increase, as Wharton and colleagues described in their 2022 clinical practice recommendations. Coffee on an empty stomach during that window is the most common pattern in people who report that coffee "stopped agreeing with them." The same coffee after a small protein-containing breakfast, or on day four of the injection cycle, frequently causes nothing.
A short trial separates the causes. A week on decaffeinated coffee at the same time and volume tells a person whether caffeine is the trigger, since decaf still stimulates acid but carries almost none of the stimulant. If the nausea persists on decaf, the problem is the coffee, the acid, or the empty stomach. If it clears, it was the caffeine, and a smaller dose or a later cup is the fix. Boekema and colleagues reviewed coffee's effects on the gut in 1999 and found that it does not itself slow gastric emptying, so coffee is not compounding the delay. It is only sitting in it.
Can coffee help with constipation on a GLP-1 medication?
Yes, and this is one of the more useful overlaps. Constipation affected about 24 percent of adults on semaglutide 2.4 mg versus 11 percent on placebo in the pooled STEP data, and it is the gastrointestinal effect most likely to persist after nausea fades. Coffee is a documented colonic stimulant. Rao and colleagues showed in the European Journal of Gastroenterology and Hepatology in 1998 that caffeinated coffee increased colonic motor activity by about 60 percent over water and 23 percent over decaffeinated coffee, an effect similar in size to a 1,000 kcal meal.
The response is fast and not entirely about caffeine. Brown and colleagues reported in Gut in 1990 that coffee triggered distal colonic motor activity within about four minutes in susceptible people, which is quicker than caffeine can reach the blood in meaningful quantities. Decaffeinated coffee produced a similar response. The likely explanation is a gastrocolic reflex triggered by coffee's other components, with caffeine adding to it once absorbed. For someone whose bowel habit has slowed on a GLP-1 medication, a morning coffee is a low-cost first step alongside fluid and fibre.
Coffee also counts toward fluid, which surprises people. Killer and colleagues compared four cups of coffee a day with the same volume of water in habitual coffee drinkers in PLoS One in 2014 and found no difference in total body water, 24-hour urine output, or blood markers of hydration. The diuretic effect of caffeine is real in people who rarely consume it and at high doses, but tolerance develops within days. Since thirst is blunted on GLP-1 medications and dehydration worsens constipation, a coffee that a person actually drinks is more useful than a glass of water they forget.
Colonic motor activity after different stimuli, indexed to water as 100
Relative values derived from Rao and colleagues 1998, who reported caffeinated coffee at about 60 percent above water and 23 percent above decaf, and comparable to a 1,000 kcal meal. Twelve healthy volunteers, ambulatory colonic manometry.
Decaf did about half the work of regular coffee, which points to compounds other than caffeine contributing.
What does caffeine do to blood pressure, heart rate, and sleep on a GLP-1 medication?
Caffeine raises blood pressure acutely, GLP-1 medications raise resting heart rate slightly, and both interfere with sleep in ways that undermine the protocol. Noordzij and colleagues pooled 16 trials in the Journal of Hypertension in 2005 and found that a 200 to 300 mg caffeine dose raised systolic pressure by about 8.1 mmHg and diastolic by about 5.7 mmHg in the hours afterward. Habitual coffee drinking, measured over weeks, raised pressure by only about 2.4 and 1.2 mmHg, because tolerance develops. GLP-1 receptor agonists lower blood pressure by a few mmHg over months through weight loss, so the two run in opposite directions and the net effect for a habitual drinker is small.
Heart rate is a different matter. Semaglutide raised resting heart rate by about 1 to 4 beats per minute in the STEP trials, and tirzepatide by a similar amount in SURMOUNT, an effect that persists for as long as the drug is taken. Caffeine's effect on resting heart rate is small and variable, but it lowers the threshold for palpitations in people who are sensitive to them. Someone who never noticed their heartbeat before and now notices it after coffee is experiencing a real, additive, and usually harmless effect. If it is accompanied by light-headedness, the first thing to check is fluid and sodium intake, both of which tend to fall on these medications.
Sleep is where coffee does its quietest damage. Drake and colleagues showed in the Journal of Clinical Sleep Medicine in 2013 that 400 mg of caffeine taken six hours before bed reduced objectively measured sleep by more than an hour, while participants' own estimates of the loss were much smaller. Gardiner and colleagues pooled 24 studies in Sleep Medicine Reviews in 2023 and calculated that a standard coffee containing about 107 mg should be finished 8.8 hours before bed, and a 218 mg pre-workout dose 13.2 hours before, to avoid measurable reductions in total sleep time. Short sleep raises ghrelin, lowers leptin, and increases next-day energy intake, which works directly against what the GLP-1 medication is doing.
Blood pressure effect of caffeine, mmHg
From the Noordzij 2005 meta-analysis. Acute values follow a 200 to 300 mg caffeine dose; chronic values reflect regular coffee intake measured over at least a week.
- Acute caffeine dose
- Habitual coffee
Tolerance removes most of the pressor effect within days of regular use.
Hours before bedtime to finish caffeine and avoid sleep loss
From the Gardiner 2023 systematic review and meta-analysis in Sleep Medicine Reviews. Cutoffs are population averages; slow CYP1A2 metabolisers need longer.
For an 11 pm bedtime, the last standard coffee lands at about 2 pm.
Does caffeine affect blood sugar for people on a GLP-1 protocol?
Acutely, caffeine makes insulin work less well. Keijzers and colleagues gave healthy volunteers 3 mg/kg of caffeine, about two cups' worth, and measured a 15 percent reduction in insulin sensitivity by clamp in Diabetes Care in 2002. Lane and colleagues extended this to people with type 2 diabetes in 2008, finding that 500 mg of caffeine a day raised average daytime glucose by about 8 percent and post-meal glucose by more, using continuous glucose monitoring. The mechanism is adenosine receptor blockade in muscle and a rise in adrenaline, both of which reduce glucose uptake for a few hours.
Long-term coffee drinking points the other way. Ding and colleagues pooled 28 cohort studies with over a million participants in Diabetes Care in 2014 and found that six cups of coffee a day was associated with a 33 percent lower risk of type 2 diabetes compared with none, with decaffeinated coffee showing a similar though smaller association. The protective compounds appear to be chlorogenic acids and other polyphenols rather than caffeine. Greenberg and colleagues showed in 2010 that decaffeinated coffee taken with a glucose load raised the body's own GLP-1 response and lowered the glucose peak in overweight men, a small study but a mechanistically neat one.
For someone tracking glucose on a GLP-1 protocol, the acute effect is worth knowing about and not worth worrying about. A post-coffee glucose reading that runs a little higher is an expected caffeine effect, not a sign the medication has stopped working. It does not approach the size of the drug's effect on glucose, and the long-term association favours coffee drinkers. Anyone on insulin or a sulfonylurea should be aware that caffeine can also mask the early warning signs of hypoglycaemia, since the tremor and racing heart of both feel similar.
How should coffee be timed around a GLP-1 microdose?
Coffee fits a GLP-1 protocol best when it follows food, arrives once rather than twice, stays under about 100 kcal, and finishes by early afternoon. Each of those rules maps onto a mechanism covered above: food buffers the acid that a slow stomach holds, patience accounts for the delayed peak, the calorie ceiling protects the protein target, and the afternoon cutoff protects the sleep that regulates appetite. None of them requires giving anything up.
The injection cycle adds a second layer. The one to two days after an injection are when gastric emptying is slowest and nausea most likely, so that is when coffee on an empty stomach is most likely to backfire. Some people find it simpler to drink decaf on injection day and the day after, then return to regular coffee for the rest of the week. Others move the injection to the evening so that the peak effect passes overnight and the morning coffee lands in a calmer stomach. Both approaches are reasonable, and the table below covers the situations that come up most often.
| Situation | What is happening | Practical approach |
|---|---|---|
| First coffee on an empty stomach the morning after an evening injection | Acid on an empty, slow-emptying stomach during the drug's peak effect | Move the first cup to after a small protein-containing breakfast, or start with a half-strength cup. If nausea still tracks the coffee rather than the injection, a week on decaf tells you whether the caffeine or the coffee itself is the trigger. |
| A second cup within 30 minutes because the first one 'did nothing' | Delayed gastric emptying has pushed the caffeine peak later, not removed it | Wait at least 60 to 90 minutes before deciding a cup has failed. On a GLP-1 medication the peak arrives later and flatter, and stacking a second dose on top of a delayed first one produces jitteriness, palpitations, and an afternoon crash. |
| A large milky or syrup-based coffee standing in for lunch | 200 to 400 kcal of mostly sugar and fat displacing a protein meal | Treat any coffee over about 100 kcal as a snack, not a drink. On a reduced appetite the protein target is hard to reach, and a blended coffee drink uses up the room a meal needed. Black coffee, an americano, or a small latte keeps the calories where they belong. |
| Coffee after 2 pm and sleep that has quietly shortened | Caffeine half-life of around five hours colliding with bedtime | The Gardiner 2023 review put the cutoff for a standard coffee at about 8.8 hours before bed. Short sleep raises ghrelin and next-day intake, which works directly against the protocol. Switching to decaf after lunch is the single highest-value change for most people. |
| Light-headedness, a racing heart, or a headache after coffee | Caffeine's acute pressor effect on top of a lowered fluid and sodium intake, plus the small resting heart rate rise from the GLP-1 medication | Check fluid intake first, since thirst is blunted on these medications. If palpitations persist, reduce the caffeine dose and mention it to the prescriber. Anyone on blood pressure medication should have their readings reviewed, because weight loss often changes the dose those drugs need. |
400 mg
Daily caffeine intake the FDA cites as not generally associated with harm in healthy adults, unchanged by a GLP-1 medication
~5 h
Typical caffeine half-life, which is unaffected by a GLP-1 medication even though the peak arrives later
0
Published studies measuring caffeine pharmacokinetics directly in people taking a GLP-1 receptor agonist
The coffee did not change. The stomach did.
Nothing about a GLP-1 medication makes coffee unsafe, and nothing about coffee makes the medication work better or worse in any way that matters. What the medication does is change the terrain: a stomach that empties slowly, an appetite that no longer prompts a meal, a thirst signal that has gone quiet, and a resting heart rate a few beats higher than before. Coffee interacts with all four, and every complaint people raise about coffee on a GLP-1 protocol traces back to one of them. The delayed peak explains the second-cup jitters. The held acid explains the morning nausea. The absent appetite explains the 380 kcal drink that replaced lunch. The evidence for each of these is solid, the evidence for any direct interaction is nonexistent, and the gap in the literature, a direct caffeine pharmacokinetic study on a GLP-1 medication, is worth stating plainly rather than filling with guesses.
"The first cup was not weak. It was late. Most of what goes wrong with coffee on a GLP-1 medication is a timing problem wearing a side effect's clothes."
Frequently asked questions
Can you drink coffee while microdosing a GLP-1 medication?
Yes. There is no listed drug interaction between caffeine and semaglutide, tirzepatide, or any other GLP-1 receptor agonist, and coffee was not restricted in the STEP or SURMOUNT trials. The US Food and Drug Administration considers up to 400 mg of caffeine a day, roughly four 8 oz cups of brewed coffee, to be a level not generally associated with harm in healthy adults. The practical issues are about timing, nausea, calories, and sleep rather than any chemical conflict between the two.
Does a GLP-1 medication change how caffeine is absorbed?
Probably, and in the direction of later and flatter. GLP-1 receptor agonists slow gastric emptying, and caffeine is absorbed mainly in the small intestine, so it has to wait for the stomach to release it. The Ozempic prescribing information reports that semaglutide reduced the exposure of oral paracetamol in the first hour by about 27 percent and its peak by about 23 percent, with no change in total exposure over five hours. Caffeine has not been measured directly, but paracetamol is a standard marker for exactly this kind of absorption, so a delayed caffeine peak is the expected result.
Does coffee add to the appetite suppression of a GLP-1 microdose?
Modestly at best. Schubert and colleagues reviewed the evidence in 2017 and found that coffee consumed 30 minutes to four hours before a meal reduced energy intake at that meal in some studies, but the effects were small and inconsistent. Caffeine raises resting metabolic rate by roughly 3 to 4 percent for a few hours after a dose, which is about 50 to 100 kcal a day in most adults. Against the 24 to 35 percent reduction in energy intake that semaglutide produces, coffee is a rounding error, and a sweetened coffee drink can easily reverse the sign.
Does coffee make GLP-1 nausea or reflux worse?
It can, mainly through acid and timing. Coffee stimulates gastric acid secretion, and reflux symptoms are already more common on GLP-1 medications, with the Wegovy prescribing information listing gastro-oesophageal reflux disease in about 5 percent of adults on semaglutide 2.4 mg versus about 1 percent on placebo. A slow-emptying stomach holds that acid longer. Drinking coffee after a small meal rather than on an empty stomach, and keeping it away from the hours after an injection when nausea peaks, resolves most of the problem.
Can coffee help with constipation on a GLP-1 medication?
Yes, and the effect is one of the better documented properties of coffee. Rao and colleagues showed in 1998 that caffeinated coffee stimulated colonic motor activity about 60 percent more than water and 23 percent more than decaffeinated coffee, an effect comparable to a 1,000 kcal meal. Brown and colleagues reported in 1990 that the response begins within about four minutes of drinking, which is too fast for caffeine alone and points to other compounds in coffee as well. Constipation affected about 24 percent of adults on semaglutide 2.4 mg versus 11 percent on placebo, so a morning coffee is a reasonable first step alongside fluid and fibre.
Does coffee dehydrate you on a GLP-1 protocol?
Not in habitual drinkers at normal intakes. Killer and colleagues compared four cups of coffee a day with the same volume of water in regular coffee drinkers in 2014 and found no difference in total body water, urine output, or blood markers of hydration. Coffee therefore counts toward the two to three litres of fluid a day that people on GLP-1 medications are usually advised to aim for. The diuretic effect of caffeine is real at high doses in people who rarely consume it, but it fades with regular use.
Does caffeine affect blood pressure, heart rate, or sleep on a GLP-1 medication?
Caffeine raises blood pressure acutely by about 8 mmHg systolic and 6 mmHg diastolic in the hours after a 200 to 300 mg dose, according to the Noordzij 2005 meta-analysis, though habitual coffee drinking raises it by only about 2 mmHg on average. GLP-1 medications independently raise resting heart rate by about 1 to 4 beats per minute. On sleep, Drake and colleagues found in 2013 that 400 mg of caffeine taken six hours before bed cut objectively measured sleep by more than an hour, and the Gardiner 2023 review put the cutoff for a standard coffee at about 8.8 hours before bedtime.
Does caffeine affect blood sugar for people on a GLP-1 protocol?
Acutely, caffeine reduces insulin sensitivity. Keijzers and colleagues found in 2002 that a 3 mg/kg dose lowered insulin sensitivity by about 15 percent in healthy volunteers, and Lane and colleagues reported in 2008 that 500 mg a day raised average daytime glucose by about 8 percent in adults with type 2 diabetes. Habitual coffee drinking, by contrast, is associated with lower type 2 diabetes risk, with the Ding 2014 meta-analysis reporting about a 33 percent lower risk at six cups a day compared with none. For someone tracking glucose on a GLP-1 protocol, the acute effect is worth knowing about, but it does not undo the drug's effect and there is no reason to stop drinking coffee because of it.
Clinical references
- Novo Nordisk. Ozempic (semaglutide) injection: prescribing information, section 12.3, clinical pharmacology. US Food and Drug Administration; 2017, with subsequent revisions.
- Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information. US Food and Drug Administration; 2021, with subsequent revisions.
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754-762.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251.
- US Food and Drug Administration. Spilling the beans: how much caffeine is too much? Consumer update; 2018, with subsequent revisions.
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the safety of caffeine. EFSA Journal. 2015;13(5):4102.
- Schubert MM, Irwin C, Seay RF, Clarke HE, Allegro D, Desbrow B. Caffeine, coffee, and appetite control: a review. International Journal of Food Sciences and Nutrition. 2017;68(8):901-912.
- Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. American Journal of Clinical Nutrition. 1989;49(1):44-50.
- Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19.
- Boekema PJ, Samsom M, van Berge Henegouwen GP, Smout AJ. Coffee and gastrointestinal function: facts and fiction. A review. Scandinavian Journal of Gastroenterology. 1999;34(Suppl 230):35-39.
- Rao SS, Welcher K, Zimmerman B, Stumbo P. Is coffee a colonic stimulant? European Journal of Gastroenterology and Hepatology. 1998;10(2):113-118.
- Brown SR, Cann PA, Read NW. Effect of coffee on distal colon function. Gut. 1990;31(4):450-453.
- Killer SC, Blannin AK, Jeukendrup AE. No evidence of dehydration with moderate daily coffee intake: a counterbalanced cross-over study in a free-living population. PLoS One. 2014;9(1):e84154.
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension. 2005;23(5):921-928.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Drake C, Roehrs T, Shambroom J, Roth T. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. Journal of Clinical Sleep Medicine. 2013;9(11):1195-1200.
- Gardiner C, Weakley J, Burke LM, et al. The effect of caffeine on subsequent sleep: a systematic review and meta-analysis. Sleep Medicine Reviews. 2023;69:101764.
- Keijzers GB, De Galan BE, Tack CJ, Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care. 2002;25(2):364-369.
- Lane JD, Feinglos MN, Surwit RS. Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes. Diabetes Care. 2008;31(2):221-222.
- Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care. 2014;37(2):569-586.
- Greenberg JA, Owen DR, Geliebter A. Decaffeinated coffee and glucose metabolism in young men. Diabetes Care. 2010;33(2):278-280.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and is not a substitute for the prescriber or clinician responsible for your care. Nothing here describes a treatment for constipation, reflux, nausea, hypertension, insomnia, obesity, type 2 diabetes, or any other condition, and no GLP-1 receptor agonist is approved for use in combination with caffeine for any purpose. GLP-1 microdosing is an off label approach, no published study has measured caffeine pharmacokinetics in people taking a GLP-1 receptor agonist, and several charts in this article contain illustrative, conceptual, or approximated values, labelled as such, which should not be read as measured results or as targets. Do not start, stop, or change the dose of insulin, a sulfonylurea, a blood pressure medication, or any other medication on the basis of this article. Persistent palpitations, chest pain, fainting, severe or persistent vomiting, or a blood glucose reading below 3.9 mmol/L requires prompt medical review. Pregnant people and anyone with a heart rhythm disorder or uncontrolled blood pressure should follow their clinician's guidance on caffeine.